# Universal CAR-T Cells (BRL-301) in Relapse or Refractory Autoimmune Diseases

> **NCT05859997** · NA · ENROLLING_BY_INVITATION · sponsor: **Bioray Laboratories** · enrollment: 15 (estimated)

## Conditions studied

- Systemic Lupus Erythematosus (SLE)
- Sjogren's Syndrome
- Systemic Sclerosis
- Inflammatory Myopathy
- ANCA Associated Systemic Vasculitis
- Antiphospholipid Syndrome

## Interventions

- **BIOLOGICAL:** BRL-301

## Key facts

- **NCT ID:** NCT05859997
- **Lead sponsor:** Bioray Laboratories
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2023-05-17
- **Primary completion:** 2024-05-27
- **Final completion:** 2025-05-27
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2024-11-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05859997

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05859997, "Universal CAR-T Cells (BRL-301) in Relapse or Refractory Autoimmune Diseases". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05859997. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*